Dune Medical Devices’ novel intraoperative breast cancer probe uses Radio Frequency (RF) Spectroscopy to provide physicians with the malignancy status of breast cancer margins in real time.
Following lumpectomy, cancer patients found to have positive (malignant) surgical margins typically require a second surgery, with added expense and trauma, to reshave tumor sites for additional tissue removal. The Dune hand-held probe, which is not yet FDA cleared, holds significant promise to reduce re-excision procedures, improve patient outcomes and minimize surgical expenses.
October 30, 2026 
